Binding in Medical Technology
Navigation Links
Binding in Medical Technology
... demonstrating that antisense reduction of retinal binding protein 4 (RBP4) caused significant improvements ... Antisense Inhibition of cAMP Response Element binding Protein (CREB)
Expression Lowers Plasma ... Knockdown of Carbohydrate Response Element binding Protein (ChREBP) in
Liver Protects Against ...
... "The data we present show the monovalent binding to normal cells of other antibodies confirming ... normal cells because it is capable of monovalent binding to very low expressions of EGFR whereas nimotuzumab's monovalent binding is transient. It is this transient ...
... such as Parkinson's disease, where metal binding is believed to induce the pathological aggregation of proteins. The discovery regarding the metal binding properties of OXIGON(TM) was reported by ... interested to learn that OXIGON(TM) has metal binding properties." Dr. Chain added: "These data fit ...
... side effects were closely correlated with the binding of these molecules in the PDE4 enzymatic active ... the deCODE chemistry team to identify a novel binding site for allosteric modulators in the PDE4 regulatory domain. binding of an allosteric modulator at that site ...
... EGFr is central to its role in signaling, and binding of HuMax-EGFr (zalutumumab) results in effective ... EGFr is central to its role in signaling, and binding of HuMax-EGFr (zalutumumab) results in effective ... activity known as ADCC, block growth factor binding to EGF receptors, and we now established that ...
... MDV3100: blocks the androgen receptor with greater binding affinity than bicalutamide; impairs nuclear translocation and blocks DNA binding of the androgen receptor, one of the key steps required for ...
... receptor antagonist. RAPAFLO(TM) maximizes target organ activity by binding with high affinity to the alpha (1A) receptors concentrated in the ... and results in improved urine flow and a reduction in BPH symptoms. The binding affinity for the alpha (1B) receptors that cause smooth muscle in ...
... endothelium), creating a specific target for anti-cancer treatments. By binding to PS, the antibodies are believed to help mobilize the body's immune ... the availability of anti-PS antibodies that vary in their mode of binding or in their specific immunomodulatory activity broadens the potential ...
... MDX-1338, a fully human anti-CXCR4 antibody, effectively blocked the binding of CXCR4 to its ligand, CXCL12, thereby inhibiting chemotaxis and ... models. The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates (Abstract #1722) ...
... several promising antibodies in preclinical evaluation that vary in their binding profile and in their specific immunomodulatory activity. The unique ... of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system ...
... into the body, tend to loose certain capabilities required for effective binding and retention within injured heart tissue such as that occurring after a ... be substantially improved through a targeting mechanism that involves the binding of the CXC chemokine receptor 4 (found on these stem cells in the bone ...
... a first clinical phase 1 trial in mid 2009; -- MT228, a glycolipid binding human antibody in development by Eisai for the treatment of melanoma, is ... cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. Previous attempts have shown the potential of T cells to treat ...
... agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive ... these receptors, results in its accumulation in the malignant tissue. This binding is followed by internalization and retention of the cytotoxic ...
... system, and skin. Amigal, a pharmacological chaperone, acts by selectively binding to the misfolded enzyme responsible for Fabry disease, alpha-GAL. After binding to the enzyme, Amigal promotes the proper folding, processing, and ...
... BRIDION(R) (sugammadex) injection, the first and only selective relaxant binding agent (SRBA) and the first major pharmaceutical advance in the field of ... BRIDION (sugammadex) BRIDION, the first and only selective relaxant binding agent (SRBA), is the first major pharmaceutical advance in the field of ...
... FDA approval, sugammadex will be the first and only selective relaxant binding agent (SRBA) and will give anesthesiologists the ability to rapidly and ... 19, 2007. About Sugammadex Sugammadex is a novel selective relaxant binding agent (SRBA) under development by Organon, a part of Schering-Plough ...
... improvement in urine flow and a reduction in BPH symptoms. The selective binding of silodosin to the alpha (1A) receptors is substantially greater than the binding to the cardiovascular-associated alpha (1B) receptors and thereby ...
... endothelial growth factor (VEGF). R84 selectively blocks VEGF from binding only to VEGF receptor 2 (VEGFR2), while non-selective agents such as ... VEGF-induced angiogenesis in tumor tissue. Dr. Brekken commented, "VEGF binding to VEGFR2 on blood vessels is a primary driver in promoting the ...
... not inhibit the activities of DDP-IV, TC-PTP or SHP-2 nor inhibit ligand binding to the CB1 or 5HT2C receptors. Additional in vitro testing demonstrated ... is a reversible, allosteric, noncompetitive inhibitor of PTP-1B, binding to a site different from the catalytic site of PTP-1B. Data also ...
... (Nasdaq: KOSN ) today announced that it has successfully reached a binding agreement with the U.S. Food and Drug Administration (FDA) on the design ... the absence of these developments, "completion of a SPA with FDA provides binding agreement relative to design and analysis of key Phase 3 trial(s) such ...
... substance and has no known potential for abuse or dependence. Guanfacine, the active ingredient in INTUNIV, is thought to work directly by binding selectively to alpha-2A adrenergic receptors located in the prefrontal cortex - an area of the brain that has been linked to ADHD.(4-6) Stimulation ...
... tumors. Brostallicin was shown to affect DNA in both dividing and quiescent cells. Its actions can be followed by induction of a specific DNA binding protein foci that can be detected in circulating blood cells. Importantly, brostallicin was active in a trabectedin-resistant cell line. ...
... Opportunities and Challenges." It summarizes the recent increased interest in this drug category. Opioid medications are chemicals that work by binding to specific receptors, particularly in the nervous system and gastrointestinal tract; decrease perception of pain and reaction to pain; and increase ...
... poor memory to consume a supplement (Prevagen(R), www.prevagen.com ) containing a protein found in jellyfish that buffers calcium by binding to it," says Underwood. "After 90 days, 63% of the volunteers reported less forgetfulness, 81% reported they required fewer reminders to ...
... estimated at more than US$500 million. VA106483 is a novel small molecule drug candidate that exerts its effect directly in the kidney by binding to vasopressin (V2) receptors, which regulate water balance. It was discovered by Vantia from its extensive drug candidate library. The ...
... over standard anthracyclines and the rational design modifications to the chemical compound believed to be responsible for enhanced DNA damage and binding to topoisomerase II enzyme, a key target for anthracycline mediated tumor death. These modifications are also hypothesized by the authors to underlie ...
... signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further ...
... including mTORC1/2, DNA-PK, PLK-1, CK2, ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to integrins that are expressed on the surface of new tumor vasculature and within the tumor compartment. In preclinical xenograft models ...
... including mTORC1/2, DNA-PK, PLK-1, CK2, ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to specific integrins that are expressed on the surface of new tumor vasculature and within the tumor compartment. In preclinical xenograft ...
... substance and has no known mechanism for abuse or dependence. Guanfacine, the active ingredient in INTUNIV, is thought to work directly by binding selectively to alpha-2A adrenergic receptors located in the prefrontal cortex. The prefrontal cortex is an area of the brain associated with working ...
... Glivec in GIST Glivec is a type of treatment called a tyrosine kinase inhibitor.(13) It works in GIST by targeting the KIT protein, binding to it and preventing it from sending continuous signals to the cancer cells to grow and divide.(14) Glivec has been available to treat people with ...
... which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is ...
... "The data we present show the monovalent binding to normal cells of other antibodies confirming ... normal cells because it is capable of monovalent binding to very low expressions of EGFR whereas nimotuzumab's monovalent binding is transient. It is this transient ...
... such as Parkinson's disease, where metal binding is believed to induce the pathological aggregation of proteins. The discovery regarding the metal binding properties of OXIGON(TM) was reported by ... interested to learn that OXIGON(TM) has metal binding properties." Dr. Chain added: "These data fit ...
... side effects were closely correlated with the binding of these molecules in the PDE4 enzymatic active ... the deCODE chemistry team to identify a novel binding site for allosteric modulators in the PDE4 regulatory domain. binding of an allosteric modulator at that site ...
... EGFr is central to its role in signaling, and binding of HuMax-EGFr (zalutumumab) results in effective ... EGFr is central to its role in signaling, and binding of HuMax-EGFr (zalutumumab) results in effective ... activity known as ADCC, block growth factor binding to EGF receptors, and we now established that ...
Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
... to develop individualized plans is the phosphate binding ratio (PBR). PBR signifies the number of grams ... lanthanum, which has a high PBR. In addition, the binding power of FOSRENOL, in vitro, was not ... has a high affinity for phosphate and works by binding to dietary phosphorus in the gastrointestinal ...... MDV3100: blocks the androgen receptor with greater binding affinity than bicalutamide; impairs nuclear translocation and blocks DNA binding of the androgen receptor, one of the key steps required for ...
... receptor antagonist. RAPAFLO(TM) maximizes target organ activity by binding with high affinity to the alpha (1A) receptors concentrated in the ... and results in improved urine flow and a reduction in BPH symptoms. The binding affinity for the alpha (1B) receptors that cause smooth muscle in ...
... endothelium), creating a specific target for anti-cancer treatments. By binding to PS, the antibodies are believed to help mobilize the body's immune ... the availability of anti-PS antibodies that vary in their mode of binding or in their specific immunomodulatory activity broadens the potential ...
... MDX-1338, a fully human anti-CXCR4 antibody, effectively blocked the binding of CXCR4 to its ligand, CXCL12, thereby inhibiting chemotaxis and ... models. The critical role of cleavable linkers for minor groove binding alkylating agent (MGBA) based antibody-drug conjugates (Abstract #1722) ...
... several promising antibodies in preclinical evaluation that vary in their binding profile and in their specific immunomodulatory activity. The unique ... of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system ...
AACR Data Highlights InNexus Preclinical Antibody Candidate
... - Additional Presentations Underscore Potency, binding Capabilities for Antibody Pipeline And Novel Technologies - ... and " Oxidative Modification Of An Anti-CD20 Antibody Imparts Autophilic binding Kinetics ", (AACR# 1230). Posters and company representatives will also ...... into the body, tend to loose certain capabilities required for effective binding and retention within injured heart tissue such as that occurring after a ... be substantially improved through a targeting mechanism that involves the binding of the CXC chemokine receptor 4 (found on these stem cells in the bone ...
... a first clinical phase 1 trial in mid 2009; -- MT228, a glycolipid binding human antibody in development by Eisai for the treatment of melanoma, is ... cannot engage T cells because T cells lack the appropriate receptors for binding antibodies. Previous attempts have shown the potential of T cells to treat ...
... agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive ... these receptors, results in its accumulation in the malignant tissue. This binding is followed by internalization and retention of the cytotoxic ...
... system, and skin. Amigal, a pharmacological chaperone, acts by selectively binding to the misfolded enzyme responsible for Fabry disease, alpha-GAL. After binding to the enzyme, Amigal promotes the proper folding, processing, and ...
... BRIDION(R) (sugammadex) injection, the first and only selective relaxant binding agent (SRBA) and the first major pharmaceutical advance in the field of ... BRIDION (sugammadex) BRIDION, the first and only selective relaxant binding agent (SRBA), is the first major pharmaceutical advance in the field of ...
European Union's CHMP Issues Positive Opinion on Sugammadex
... approval, sugammadex will be the first and only selective relaxant binding agent (SRBA) and will enable anesthesiologists to rapidly and predictably ... group. About sugammadex Sugammadex is a novel selective reversal binding agent (SRBA) under development by Schering-Plough Corporation. It will ...Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
... human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug, approved in the United States in ... human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug is also being investigated for ...Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
... most promising monoclonal antibodies/projects and to locate the antibody binding epitope. "These results clearly show the importance of understanding ... the most promising therapeutic antibody and to locate the antibody binding epitope. For more information, please contact: Mr.Hans Johansson, CEO ...... FDA approval, sugammadex will be the first and only selective relaxant binding agent (SRBA) and will give anesthesiologists the ability to rapidly and ... 19, 2007. About Sugammadex Sugammadex is a novel selective relaxant binding agent (SRBA) under development by Organon, a part of Schering-Plough ...
... improvement in urine flow and a reduction in BPH symptoms. The selective binding of silodosin to the alpha (1A) receptors is substantially greater than the binding to the cardiovascular-associated alpha (1B) receptors and thereby ...
... endothelial growth factor (VEGF). R84 selectively blocks VEGF from binding only to VEGF receptor 2 (VEGFR2), while non-selective agents such as ... VEGF-induced angiogenesis in tumor tissue. Dr. Brekken commented, "VEGF binding to VEGFR2 on blood vessels is a primary driver in promoting the ...
... not inhibit the activities of DDP-IV, TC-PTP or SHP-2 nor inhibit ligand binding to the CB1 or 5HT2C receptors. Additional in vitro testing demonstrated ... is a reversible, allosteric, noncompetitive inhibitor of PTP-1B, binding to a site different from the catalytic site of PTP-1B. Data also ...
ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
... Lead Discovery (FBLD) Project with CHDI, Inc. FBLD involves the binding of small compounds, "fragments," to the active sites of protein drug ... into larger, drug-like compounds that are thought to be more efficiently binding than compounds resulting from HTS methodologies. Several compounds based ...... (Nasdaq: KOSN ) today announced that it has successfully reached a binding agreement with the U.S. Food and Drug Administration (FDA) on the design ... the absence of these developments, "completion of a SPA with FDA provides binding agreement relative to design and analysis of key Phase 3 trial(s) such ...
... substance and has no known potential for abuse or dependence. Guanfacine, the active ingredient in INTUNIV, is thought to work directly by binding selectively to alpha-2A adrenergic receptors located in the prefrontal cortex - an area of the brain that has been linked to ADHD.(4-6) Stimulation ...
... tumors. Brostallicin was shown to affect DNA in both dividing and quiescent cells. Its actions can be followed by induction of a specific DNA binding protein foci that can be detected in circulating blood cells. Importantly, brostallicin was active in a trabectedin-resistant cell line. ...
... Opportunities and Challenges." It summarizes the recent increased interest in this drug category. Opioid medications are chemicals that work by binding to specific receptors, particularly in the nervous system and gastrointestinal tract; decrease perception of pain and reaction to pain; and increase ...
... poor memory to consume a supplement (Prevagen(R), www.prevagen.com ) containing a protein found in jellyfish that buffers calcium by binding to it," says Underwood. "After 90 days, 63% of the volunteers reported less forgetfulness, 81% reported they required fewer reminders to ...
... estimated at more than US$500 million. VA106483 is a novel small molecule drug candidate that exerts its effect directly in the kidney by binding to vasopressin (V2) receptors, which regulate water balance. It was discovered by Vantia from its extensive drug candidate library. The ...
... over standard anthracyclines and the rational design modifications to the chemical compound believed to be responsible for enhanced DNA damage and binding to topoisomerase II enzyme, a key target for anthracycline mediated tumor death. These modifications are also hypothesized by the authors to underlie ...
... signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second immunostimulatory mechanism. Further ...
... including mTORC1/2, DNA-PK, PLK-1, CK2, ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to integrins that are expressed on the surface of new tumor vasculature and within the tumor compartment. In preclinical xenograft models ...
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
... been shown to induce apoptosis directly by operating as a BH3 mimetic and indirectly as an independent upregulator of Noxa and Puma. By blocking the binding of Bcl-2 family members with proapoptotic proteins and upregulating specific proapoptotic factors, AT-101 lowers the threshold for cancer cells to ...Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
... on cell surfaces and forms a protein-receptor complex that makes it possible for the anthrax toxins to enter the cells. Raxibacumab blocks the binding of protective antigen to cell surfaces and prevents the anthrax toxins from entering and killing the cells. ABOUT HUMAN GENOME SCIENCES ...... including mTORC1/2, DNA-PK, PLK-1, CK2, ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to specific integrins that are expressed on the surface of new tumor vasculature and within the tumor compartment. In preclinical xenograft ...
... substance and has no known mechanism for abuse or dependence. Guanfacine, the active ingredient in INTUNIV, is thought to work directly by binding selectively to alpha-2A adrenergic receptors located in the prefrontal cortex. The prefrontal cortex is an area of the brain associated with working ...
... Glivec in GIST Glivec is a type of treatment called a tyrosine kinase inhibitor.(13) It works in GIST by targeting the KIT protein, binding to it and preventing it from sending continuous signals to the cancer cells to grow and divide.(14) Glivec has been available to treat people with ...
... which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is ...
Other ContentsconjunctivitisconjunctivitisarthritisarthritisarthritisarthritisarthritisarthritisarthritiscroupgastroenteritisgastroenteritisgastroenteritishemorrhagichemorrhagichemorrhagichemorrhagicpneumoniapneumoniapneumoniapneumoniapneumoniapneumoniaOther TagsSplintSporesSteinSteinSteinSteinStasisStasisStasisStasisStenosisOther Tagsplatform 2platform 3platform 4platform 5share 2share 3share 4share 5share 6share 7share 8share 9share 10departments 2departments 3departments 4departments 5departments 6departments 7departments 8departments 9advancement 2advancement 3advancement 4plans 2plans 3plans 4plans 5plans 6plans 7plans 8plausible 2biologically 2biologically 3test 2test 3test 4test 5test 6test 7test 8test 9test 10
(Date:11/25/2009)...he heart pumps some 250 million liters of blood th...e fibers of the heart have to be extremely durable...uer, vice chair of the Department of Medicine III ... Dr. H. A. Katus), has discovered a protein that i...scular unit, the sarcomere. In cooperation with ot...
(Date:11/24/2009)...ors to understanding how sounds associated with Na...al or if they hear it at all. , The same type o...uses to detect flaws in the space shuttle,s behemo...o peek inside the giant head of a whale. The scans... of a whale,s hearing anatomy using a breakthrough...
(Date:11/24/2009)...er 24, 2009) -- The Wildlife Conservation Society ...last remaining population of Siberian tigers has l...e of poaching and habitat loss. , WC...ls of what needs to be done to protect remaining p... The report was released by the Siberian Tige...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Rocket science leads to new whale discovery 2Report shows dramatic decline in Siberian tigers 2Palatin Technologies Inc to Report Fourth Quarter and Fiscal Year 2009 Results 3B Teleconference and Webcast to be held on September 8 2009 13859 1Palatin Technologies Inc to Report Fourth Quarter and Fiscal Year 2009 Results 3B Teleconference and Webcast to be held on September 8 2009 13859 2Delcath Systems to Present at Rodman 26 Renshaw 11th Annual Healthcare Conference 56246 1Mindray DS USA Appoints Michael Thompson Vice President of U S Ultrasound Sales 56243 1Mindray DS USA Appoints Michael Thompson Vice President of U S Ultrasound Sales 56243 2Mindray DS USA Appoints Michael Thompson Vice President of U S Ultrasound Sales 56243 3(Date:11/27/2009)..., Nov. 27 Preventing di...d fortunately every year, new vaccines are being a...accines boost immunity for the same period of time... needed to keep immunity strong? ,, In this m...rican Academy of Pediatrics, Michael Pichichero MD...
(Date:11/27/2009)...ecedented medical, economic burdens, study predict...- The number of people with diabetes in the United...rs, a new study predicts. , That would bring th...the disease, up from 23.7 million today. , , At ...abetes will triple, the study also warns, rising f...
(Date:11/27/2009)...hree new interactive anatomy education apps from M...nd health sciences learning opportunities for iPho...m, NC (Vocus) November 27, 2009 -- Modality, Inc....ivision of Wolters Kluwer Health, today announced ...ps on the App Store. Clemente’s Anatomy, Roh...
(Date:11/26/2009)...oo heavy can lead to strains or worse , ,...be nothing wrong with stuffing your turkey full to...hing with your suitcase as you pack for holiday tr...2008 in U.S. hospital emergency rooms, doctors, of...ggage-related injuries, such as muscle strains, pu...
(Date:11/26/2009)...enton Communications announces a highly effective ...ilers struggling to make an economic recovery. , ...-- Flu fears is the type of challenge that could s...cording to Dr. David Benton, business growth exper... system – The Rfactor Intensive . “...
Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Pharmacist Injects Cure for Ailing Businesses 2[0] Why Some Vaccines May Require A Booster[0] Diabetes Cases Expected to Double in 25 Years[0] Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store[2] Pack Right for the Holidays to Avoid the ER[1] Pharmacist Injects Cure for Ailing Businesses
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |